A Timeline of Australian Drug Scheduling

Why Australian drug scheduling didn't arrive fully formed

Forty-seven separate pieces of colonial legislation. That's roughly what the Commonwealth inherited when it federated in 1901: a patchwork of state pharmacy acts, poisons ordinances, and opium regulations, each drafted to fix a local problem that some other colony had already forgotten about. Anyone trying to understand drug scheduling in Australia today needs to know just how chaotic that starting point was.

Scheduling, put simply, is the practice of sorting substances into tiers according to how tightly their supply should be controlled. Our drug scheduling glossary entry covers the terminology, but the short version is that a substance's tier decides who may supply it, whether a prescription is needed, and what records must be kept.

The arguments from the early twentieth century, such as whether laudanum should require a pharmacist's signature, sound strikingly similar to debates that continue in Canberra more than a century later. In my view that continuity is the best reason to learn the history: the same tensions between access and safety keep returning in new clothes. Some things move slowly.

Federation to mid-century: competing standards and no real system

The Commonwealth Constitution gave the federal government limited powers over pharmaceutical regulation. For the first few decades, this meant state governments kept doing whatever they'd been doing, with minimal coordination. Victoria had one poisons schedule. New South Wales had another. Western Australia's framework diverged significantly from both.

The practical consequence was inconsistency. A substance could be freely sold over a counter in one jurisdiction and restricted in the next, and a product label that was lawful in one place might be unlawful a short distance away. Manufacturers and pharmacists had to track several rulebooks at once, and regulators had little ability to compare notes. If you want to see how that division of powers still shapes things, our piece on state versus federal drug regulation picks up the thread.

The first real attempt at national coordination came through the Therapeutic Goods Act 1953, which established the basis for Commonwealth involvement in drug safety. But the legislation was modest by modern standards. It set out some quality requirements for imported medicines and gave the Health Department teeth to act on adulterated products. It did not yet create the scheduling architecture that Australians now work within.

International treaties push Australia toward a national framework

That architecture, the tiered schedule system, came progressively, largely in response to international treaty obligations. Australia ratified the United Nations Single Convention on Narcotic Drugs 1961, which required signatory countries to control listed substances through domestic legislation. The 1971 Convention on Psychotropic Substances extended that logic to a much broader class of compounds. Both treaties pushed Australia toward a coherent national framework, even if the political will to actually build one took another decade to materialise.

It helps to understand what a treaty does and does not do here. An international convention binds the country, not individual citizens, so it only has practical effect once domestic law gives it teeth. That is why the treaty obligations show up in Australian life as state and Commonwealth legislation rather than as anything a person would read in the convention text. For more on the first of these instruments, see our article on the Single Convention on Narcotic Drugs, and for the later cannabis-specific decisions, UN scheduling of cannabis.

A common mistake is to assume the treaties dictate every detail. They set categories of control and minimum expectations; individual countries still decide a good deal about how to implement them, which is part of why national schedules differ from one another.

The Therapeutic Goods Administration and the modern scheduling era

The Therapeutic Goods Administration (TGA) was established within the federal Department of Health in 1989, following the Therapeutic Goods Act 1989. This is the piece of legislation that restructured how medicines are evaluated, listed, and registered in Australia; the foundation of the Australian Register of Therapeutic Goods (ARTG), which remains the central mechanism for market authorisation today. You can read more about the ARTG in our ARTG glossary entry. For the regulator's own story, see how the TGA came to be and our explainer on the TGA.

The scheduling system itself is codified in the Poisons Standard, formally, the Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP). It is a legislative instrument made under the Therapeutic Goods Act, and it is the document that classifies every scheduled substance in Australia into one of ten schedules. The states and territories then adopt these schedules into their own poisons legislation, which is why the system has real legal effect across the country. The Commonwealth proposes; the states enforce. A fuller walk-through sits in The Poisons Standard (SUSMP) explained.

The eight active schedules most people encounter run from Schedule 2 (pharmacy medicines, over-the-counter products kept behind the counter) through to Schedule 8 (Controlled Drugs), which covers substances like morphine and oxycodone that require strict prescription controls, records, and supply limits. Schedule 4 (Prescription Only) is the middle tier: not controlled drugs, but still requiring a valid prescription from an authorised health practitioner. The difference between those two tiers is a frequent source of confusion, and we unpack it in Schedule 4 vs Schedule 8.

Schedule 9 is the category that generates the most public debate. These are Prohibited Substances; compounds for which there is considered to be no acceptable therapeutic use outside of narrowly approved research or clinical contexts. Criminal penalties apply to unauthorised supply or possession under state law.

Cannabis: a long road through the schedules

Cannabis is worth tracing in detail because it illustrates how scheduling decisions interact with science, politics, and public sentiment over time, and because the trajectory is genuinely unusual.

Through most of the twentieth century, cannabis and its constituent compounds were placed in Schedule 9. Tetrahydrocannabinol (THC), the principal psychoactive compound, remained prohibited. No accepted medical use, no legal pathway for patients.

The scientific landscape began to shift in the 1990s, when researchers characterised the endocannabinoid system, a signalling network present throughout mammalian biology, involving the CB1 and CB2 receptors, among other components. This discovery reframed cannabis pharmacology entirely. It was no longer simply a matter of a plant producing intoxication; there was a biological mechanism to study.

But discovery doesn't automatically change regulation. The scheduling review process has its own pace, and the TGA's evidence requirements don't adjust simply because academic interest increases. A mechanism being identified is a starting point for research, not a verdict on whether any product should be made more available. It took another two decades for the regulatory framework to catch up in any meaningful way.

In 2016, the TGA amended the Poisons Standard to move certain cannabis-derived medicines, including cannabidiol (CBD) under specific conditions, from Schedule 9 into Schedules 4 and 8, depending on the application and preparation. This created legal pathways for medical cannabis prescriptions through the Special Access Scheme (SAS) and the Authorised Prescriber framework. For the first time, a practitioner in Australia could legally access cannabis-derived preparations for a patient through a regulated mechanism. Our guide to the Special Access Scheme explains how that pathway is structured.

Low-dose CBD and the gap between rules and reality

A further rescheduling in 2021 moved low-dose CBD products to Schedule 3, meaning they could, in principle, be sold by a pharmacist without a prescription, subject to conditions. In practice, the path to compliant Schedule 3 CBD products reaching shelves has been slower than the regulation itself, largely because Good Manufacturing Practice (GMP) requirements and ARTG registration are significant hurdles for manufacturers to clear. The standards behind that hurdle are described in TGA Good Manufacturing Practice licensing, and the reasoning behind this particular change is covered in CBD and down-scheduling in Australia.

The lesson is that a rescheduling decision is only the first step. A product still has to be made to the required quality standard, entered on the ARTG, and described in ways that respect the advertising rules before it can lawfully reach a customer. Each of those steps takes time and money, which is why a rule change on paper and a change on the shelf can be years apart.

I'll say what I think here: the 2016 change was meaningful, but the implementation lag between rescheduling and actual patient access has been, at times, frustrating to observe from the outside. The structure is sound; the administrative machinery has not always kept pace with it.

Psychedelics: Schedule 9, then a narrow reclassification

Psilocybin and MDMA followed a broadly similar trajectory to cannabis, decades in Schedule 9, followed by a contested and partial rescheduling. In February 2023, the TGA made the decision to move psilocybin (for certain treatment-resistant conditions) and MDMA (for PTSD) from Schedule 9 to Schedule 8, effective 1 July 2023. This was not a general legalisation. It created a tightly bounded pathway: Authorised Prescribers only, under a specific regulatory approval granted by the TGA. Obtaining, using, or supplying these substances outside that framework remains a serious criminal offence under state and territory law.

The TGA's own summary is clear about the limitations. The evidence base consulted, including data from international trials, was assessed as promising but not conclusive, and the framework reflects that: controlled access, not open availability. Readers wanting the detail of that decision can start with the 2023 Australian down-scheduling of psilocybin.

Notice the wording "promising but not conclusive". It is a useful phrase to keep in mind whenever a headline announces a regulatory shift, because it describes a cautious, conditional decision rather than an endorsement.

Peptides and the ongoing enforcement challenge

One area that often gets treated as outside the scheduling conversation is peptides, compounds built from chains of amino acids, linked by peptide bonds. Many peptides with research interest are in fact scheduled or unapproved in Australia, and the TGA has been active in enforcement action in recent years. Peptides marketed for performance enhancement or anti-ageing purposes frequently lack ARTG registration. Under Australian law, supplying unapproved therapeutic goods is illegal, and the TGA's enforcement team has made this an explicit priority. This isn't a grey area; it's a clear regulatory position that often gets underreported in the broader conversation about scheduling.

Part of the confusion comes from the word "research". A compound being studied in laboratories says nothing about whether it may lawfully be supplied for any purpose. The legal basis for exceptions is set out in unapproved therapeutic goods: the legal basis, and the limits on how such products may be described are covered in advertising rules for therapeutic goods.

How the drug scheduling review process works

The TGA accepts scheduling proposals through a formal process, evaluated by the Advisory Committee on Medicines Scheduling (ACMS). Proposals can come from industry, health practitioners, researchers, or the public. The committee reviews the evidence according to criteria in the Poisons Standard itself, including toxicity, potential for misuse, and whether the substance has an accepted medical use.

It's worth understanding that scheduling decisions are not the same as efficacy approvals. Moving a substance from Schedule 9 to Schedule 4 means the TGA has determined there is a plausible medical use warranting controlled access, not that the evidence base is complete or that widespread prescribing is necessarily recommended. Those are different questions. I write about the difference between these regulatory signals and proof of effect in quite a bit of detail elsewhere on this site, because conflating them is one of the most common reading errors I see.

The Poisons Standard is updated continuously. It is not a fixed document. Changes made through TGA delegate decisions can take effect within weeks. Interim scheduling decisions can be made even faster when there's an urgent public health reason. The system is more dynamic than most people realise; which makes it important to check the current version of the Standard rather than relying on summaries that may be six months out of date.

Checking the primary source matters for a simple reason: secondary summaries, including this one, capture a moment in time. The Office of Drug Control and the TGA publish the authoritative material, and the list below is the best place to begin.

Sources

• Poisons Standard (SUSMP), Therapeutic Goods Administration
• Scheduling Delegate's Final Decisions, TGA
• How Does Australia Classify Drugs?; Australian Drug Foundation
• Medicinal Cannabis Regulation, Australian Government Department of Health

, Hannah Bui, Evidence & Research-Literacy Writer